Keystone Labs Court-Ordered To Halt OTC Drug Manufacturing; Cosmetics Not Affected, It Says
This article was originally published in The Rose Sheet
Keystone Labs agrees to cease manufacturing OTC drugs following a 2013 FDA warning letter and repeated GMP violations noted during inspections, including failure to investigate sources of contamination. Firm suggests it will continue making cosmetic hair- and skin-care formulas while outsourcing OTC product manufacturing.
You may also be interested in...
Proposed regulatory reform legislation in the Senate would require FDA to review the safety of cosmetics ingredients, taking into account evaluations conducted by accredited third parties. In August, FDA requested quotes from the contractor community for developing a cosmetic hazard and risk assessment protocol and optional certification program “to show compliance with the protocol.”
Recalls reported by FDA for OTC drugs, nutritionals and personal care products.
FDA’s draft revision of Cosmetic Good Manufacturing Practices takes into account international consensus formed through harmonization efforts under the International Cooperation on Cosmetics Regulations, says the agency. The recommendations update guidelines created in 1997 and revised in 2008.